By Rich Shea, Guest Columnist
Two days ago, as part of the Foundation Fighting Blindess’ “Light the Way to a Cure” fundraising campaign, I shared the story of Corey Haas, as an example of clinical trial participants benefitting from gene therapy studies the Foundation supports. In his case, the therapy’s for a retinal disease called Leber congenital amaurosis. Today, I’d like to share the story of Dick Coulson, who has age-related macular degeneration (AMD), the leading cause of blindness in people age 55 and older. It’s also the target of two treatments that are currently in clinical, or human, trials, both of which are derived from stem cells.
At the age of 80, Dick Coulson (featured earlier this year in The New York Times) resides in Lakewood, Colorado, where he gets around with a white cane and engages in his favorite pastime, photography. Twenty-five years ago, during a routine eye exam, the doctor noticed yellow spots, otherwise known as drusen, on Dick’s retina, an early sign of AMD. Over the next 15 years, Dick’s sight got progressively worse, forcing him to give up driving and his orthodontic practice. He’s now legally blind.
Dick’s not a complainer. He’s still an active photographer, using a digital camera to shoot, then a magnifier on his computer screen to select images. And he loves to travel, even if that means asking strangers to help him find the gates for flights. Like most Foundation Fighting Blindness members, Dick also keeps up with the latest research for treatments for AMD and other retinal diseases.
As the Foundation’s CEO, Bill Schmidt, pointed out in his blog post listing the top 12 retinal-research advancements of 2012, StemCells, Inc., launched a clinical trial – one that involves human participants – for a treatment of AMD this past summer. In addition, two participants in another stem-cell-related clinical trial, this one conducted by Advanced Cell Technology (ACT), demonstrated improved vision this past year. One has AMD, the other a juvenile form called Stargardt disease.
To see a CBS News story on stem cell therapy for AMD click this image:
Stem-cell-based therapies – including those derived from a patient’s blood or skin – are among the many cutting-edge approaches to treatments the Foundation has funded for decades. The $500 million we’ve raised thus far has been funneled into both pre-clinical and clinical research, for potential gene therapy and pharmaceutical treatments as well. Considering that 10 million Americans are affected by retinal diseases – including retinitis pigmentosa, Usher syndrome and choroideremia – we’re dedicated to funding the best researchers in the most prestigious institutions worldwide.
Which brings me back to Dick Coulson. As resourceful, energetic and optimistic as he is, he supports the Foundation’s work, to ensure that people entering their post-retirement years – that’s you, Baby Boomers – don’t have to lose their vision to AMD. The Foundation’s “Light the Way to a Cure” fundraising campaign, which doubles every dollar donated, will help us keep the research momentum going. And that will lead to treatments and cures, sooner rather than later.
Please donate to FFB’s “Light the Way to a Cure” Campaign: DONATE
Rich Shea is Senior Writer at the Foundation Fighting Blindness, where he writes about research, Foundation news and people affected by retinal diseases. Previously, he was an award-winning journalist who wrote and edited for newspapers and magazines, covering subjects ranging from culture to politics to public health.
The views, opinions and positions expressed in this column are the author’s alone. They do not inherently or expressly reflect the views, opinions and/or positions of American News Report, Microcast Media Group or any of its employees, directors, owners, contractors or affiliate organizations. American News Report makes no representations as to the accuracy, completeness, currentness, suitability, or validity of any information in this column, and is not responsible or liable for any errors, omissions, or delays (intentional or not) in this information; or any losses, injuries, and or damages arising from its display, publication, dissemination, interpretation or use.
Opposing views, opinions and positions about this column are welcomed by American News Report and or Microcast Media Group. Publication or lack of publication of opposing views, opinions and/or positions does not imply, suggest or expressly reflect an endorsement or disapproval of the originating commentary on the part of American News Report or Microcast Media Group.
(1) Reader Comment
November 12, 2012
October 08, 2012
September 12, 2012
July 23, 2012
September 26, 2014
September 24, 2014
September 21, 2014
September 19, 2014
September 17, 2014
Excellent recommendation for anyone looking to improve the passage of
Gov Andy is the only person in New York who thinks that the safe act w
Cute. "They’re attributing this to general business conditions...."
Thank you Dr. Silverman for your fast action in the face of a certain
What they did to Rosen is simply astounding. That sure perked up the m